Omeprazole Zydus France

Omeprazole, the active ingredient in Omeprazole Zydus France, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease and Zollinger‑Ellison syndrome in adults.

GNH USA supplies Omeprazole Zydus France as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions: - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of the oesophageal lining. - Peptic ulcer disease: supports ulcer healing by maintaining a less acidic gastric environment. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumours. - Erosive esophagitis: aids mucosal repair and reduces further acid injury. - H. pylori eradication regimens (as adjunct): enhances the effectiveness of antibiotic‑based eradication protocols.

Adverse reactions to omeprazole are reported across a spectrum of frequency.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Diarrhoea: watery stools without blood, usually self‑limiting. - Nausea: occasional feeling of queasiness, may improve with food. - Abdominal pain: mild cramping or discomfort in the stomach region. - Flatulence: increased intestinal gas production. - Constipation: reduced bowel movements, sometimes linked to diet.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhoea. - Acute interstitial nephritis: kidney inflammation causing reduced urine output and flank pain. - Hypersensitivity reactions: rash, pruritus, or angio‑edema that may progress to anaphylaxis. - Osteoporotic fractures: increased risk of hip, wrist or vertebral fractures with long‑term use. - Vitamin B12 deficiency: reduced absorption leading to anemia or neuropathy. - Hepatotoxicity: elevated liver enzymes or jaundice indicating liver injury.

When prescribing omeprazole, clinicians should consider several safety aspects: - Assess renal function: dose adjustment may be needed in severe impairment. - Review concomitant medications: potential for drug‑drug interactions. - Evaluate for H. pylori infection: may require combination therapy. - Monitor long‑term use: assess bone health and nutrient status. - Pregnancy and lactation: weigh benefits against potential risks. - Store at below 25°C: keep in the original container, protect from moisture and light.

Omeprazole can influence the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing thrombotic risk. - Atorvastatin: increased plasma concentrations, raising the chance of myopathy. - Warfarin: enhanced anticoagulant effect, requiring INR monitoring.

Moderate Interactions (Monitor Closely): - Digoxin: modest rise in serum levels, watch for toxicity signs. - Methotrexate: decreased renal clearance, may need dose reduction. - Diazepam: elevated concentrations, monitor for sedation. - Ketoconazole: reduced absorption due to higher gastric pH.